Table 2.
Baseline demographic and clinical features of 200 chronic hepatitis C patients with interferon-alpha therapy
| Total | 3-MU group† No. (%) | 6-MU group‡ No. (%) | |
| Patient Number | 200 | 76 | 124 |
| Gender | |||
| Male | 103 | 34(44.7) | 69(55.6) |
| Female | 97 | 42(55.3) | 55(44.4) |
| Age (year) | 47.3 ± 10.4 | 45.3 ± 11.7 | |
| History of transfusion | |||
| No | 141 | 56(73.7) | 85(68.5) |
| Yes | 59 | 20(26.3) | 39(31.5) |
| Liver histopathology | |||
| Total score of necroinflammatory activity | 4.48 ± 2.56 | 4.23 ± 2.46 | |
| Fibrosis score | |||
| F3–4 | 70 | 30(39.5) | 40(32.3) |
| F0–2 | 130 | 46(60.5) | 84(67.7) |
| Pretreatment ALT value (U/L) | 117.4 ± 102.8 | 104.1 ± 95.4 | |
| Pretreatment HCV RNA level (log equivalent/mL) | 5.97 ± 0.59 | 6.01 ± 0.68 | |
| HCV genotype | |||
| 1b | 80 | 27(35.5) | 53(42.7) |
| Non-1b | 120 | 49(64.5) | 71(57.3) |
| Interferon preparation | |||
| Recombinant IFN-α-2a | 37 | 10(13.2) | 27(21.8) |
| Recombinant IFN-α-2b | 95 | 36(47.4) | 59(47.6) |
| Lymphoblastoid IFN-α-n1 | 68 | 30(39.5) | 38(30.6) |
† 3-MU group: interferon-α 3 million units thrice weekly for 24 weeks.
‡ 6-MU group: interferon-α 6 million units thrice weekly for 24 weeks.